Findings

What do systematic reviews say?

182 questions · 189 findings · 24 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 10.6%GRADE not reported 3 · 1.6%Very low 54 · 28.6%Low 62 · 32.8%Moderate 43 · 22.8%High 7 · 3.7%

Cognitive‐behavioural intervention vs controls

Fatigue · patients with fibromyalgia

1 finding from 1 review

Cognitive behavioural therapies for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 910 participants
Low

Cognitive‐behavioural intervention vs controls

Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia

1 finding from 1 review

Cognitive behavioural therapies for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 422 participants
Low

Pregabalin vs placebo at end of treatment

Fatigue · patients with fibromyalgia

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 3195 participants
High

Pregabalin vs placebo at end of treatment

Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 3139 participants
High

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Moderate

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

rolapitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Moderate

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low